LY3819253
Phase 3Small molecule
Eli LillyLY3819253 is one of 77 small molecule programs targeting Peripheral Neuropathy. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
LY3819253
Eli LillyPhase 3
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-194 trials
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT05780268·314 enrolled
ACTIV-3: Therapeutics for Inpatients With COVID-19
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04501978·2,753 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3819253. EMBL-EBI & Wellcome Sanger Institute.
- [4]